Report Detail
Global Spesolimab Market 2026 by Manufacturers, Regions, Type and Application, Forecast to 2032
- RnM4733781 |
- 24 August, 2026 |
- Global |
- 73 Pages |
- GIR |
- Pharma & Healthcare
According to our (Global Info Research) latest study, the global Spesolimab market size was valued at US$ 185 million in 2025 and is forecast to a readjusted size of US$ 332 million by 2032 with a CAGR of 7.4% during review period.
Spesolimab is a humanized monoclonal antibody that targets the interleukin-36 receptor (IL-36R). It is primarily used for the treatment of moderate to severe inflammatory skin diseases, including generalized pustular psoriasis (GPP). The drug works by blocking the IL-36 signaling pathway, thereby inhibiting the inflammatory cascade, rapidly controlling acute skin inflammation, and improving clinical symptoms. As one of the first biologic agents targeting the IL-36 pathway, spesolimab represents a significant breakthrough in the treatment of rare dermatological diseases and provides a novel targeted therapeutic option for related inflammatory conditionsIn 2025, global Stapokibart production reached approximately 85,000 units.
Spesolimab, as the first biologic targeting the interleukin-36 receptor (IL-36R), holds a first-mover advantage in the market for generalized pustular psoriasis (GPP), a rare inflammatory skin disease with high unmet medical needs. As GPP is increasingly recognized as a distinct disease entity and the key role of the IL-36 pathway in inflammatory pathogenesis continues to be validated, the clinical value of this therapy has been further enhanced Although the global GPP patient population is relatively small, the disease is characterized by severe acute flares and urgent treatment needs, giving Spesolimab a market profile of “high unit price and strong clinical necessity.” From a competitive landscape perspective, this field is still at an early stage of development. Apart from Spesolimab, only a limited number of IL-36-targeted therapies are in clinical or early development stages, resulting in relatively low competition and a temporary monopolistic advantage in the short term. However, in the long run, expanding applications of mainstream psoriasis targets such as IL-23 and IL-17 therapies, as well as the emergence of new inflammatory pathway drugs, may gradually intensify competitive pressure. Looking ahead, with expanded indications (such as other IL-36-mediated inflammatory diseases), improved diagnosis rates, and increased global market penetration, the market size of Spesolimab is expected to grow rapidly, further strengthening its influence in the rare dermatology biologics market.
This report is a detailed and comprehensive analysis for global Spesolimab market. Both quantitative and qualitative analyses are presented by manufacturers, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2025, are provided.
Key Features:
Global Spesolimab market size and forecasts, in consumption value ($ Million), sales quantity (Units), and average selling prices (US$/Unit), 2021-2032
Global Spesolimab market size and forecasts by region and country, in consumption value ($ Million), sales quantity (Units), and average selling prices (US$/Unit), 2021-2032
Global Spesolimab market size and forecasts, by Type and by Application, in consumption value ($ Million), sales quantity (Units), and average selling prices (US$/Unit), 2021-2032
Global Spesolimab market shares of main players, shipments in revenue ($ Million), sales quantity (Units), and ASP (US$/Unit), 2021-2026
The Primary Objectives in This Report Are:
To determine the size of the total market opportunity of global and key countries
To assess the growth potential for Spesolimab
To forecast future growth in each product and end-use market
To assess competitive factors affecting the marketplace
This report profiles key players in the global Spesolimab market based on the following parameters - company overview, sales quantity, revenue, price, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Boehringer Ingelheim, Catalent, Lonza, etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
Market Segmentation
Spesolimab market is split by Type and by Application. For the period 2021-2032, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type
Monoclonal Antibodies, mAbs
Polyclonal Antibodies, pAbs
Market segment by Specification
450 mg / 7.5 mL
120 mg / 1.9 mL
Market segment by Sales Channels
Hospital
Retail
Online
Market segment by Route of Administration
Intravenous Infusion, IV
Subcutaneous Injection, SC
Market segment by Application
Generalized Pustular Psoriasis (GPP)
Other Psoriasis-Related Inflammatory Conditions
IL-36-Mediated Inflammatory Skin Diseases
Others
Major players covered
Boehringer Ingelheim
Catalent
Lonza
Market segment by region, regional analysis covers
North America (United States, Canada, and Mexico)
Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)
South America (Brazil, Argentina, Colombia, and Rest of South America)
Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)
The content of the study subjects, includes a total of 15 chapters:
Chapter 1, to describe Spesolimab product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top manufacturers of Spesolimab, with price, sales quantity, revenue, and global market share of Spesolimab from 2021 to 2026.
Chapter 3, the Spesolimab competitive situation, sales quantity, revenue, and global market share of top manufacturers are analyzed emphatically by landscape contrast.
Chapter 4, the Spesolimab breakdown data are shown at the regional level, to show the sales quantity, consumption value, and growth by regions, from 2021 to 2032.
Chapter 5 and 6, to segment the sales by Type and by Application, with sales market share and growth rate by Type, by Application, from 2021 to 2032.
Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales quantity, consumption value, and market share for key countries in the world, from 2021 to 2026.and Spesolimab market forecast, by regions, by Type, and by Application, with sales and revenue, from 2027 to 2032.
Chapter 12, market dynamics, drivers, restraints, trends, and Porters Five Forces analysis.
Chapter 13, the key raw materials and key suppliers, and industry chain of Spesolimab.
Chapter 14 and 15, to describe Spesolimab sales channel, distributors, customers, research findings and conclusion.
1 Market Overview
- 1.1 Product Overview and Scope
- 1.2 Market Estimation Caveats and Base Year
- 1.3 Market Analysis by Type
- 1.3.1 Overview: Global Spesolimab Consumption Value by Type: 2021 Versus 2025 Versus 2032
- 1.3.2 Monoclonal Antibodies, mAbs
- 1.3.3 Polyclonal Antibodies, pAbs
- 1.4 Market Analysis by Specification
- 1.4.1 Overview: Global Spesolimab Consumption Value by Specification: 2021 Versus 2025 Versus 2032
- 1.4.2 450 mg / 7.5 mL
- 1.4.3 120 mg / 1.9 mL
- 1.5 Market Analysis by Sales Channels
- 1.5.1 Overview: Global Spesolimab Consumption Value by Sales Channels: 2021 Versus 2025 Versus 2032
- 1.5.2 Hospital
- 1.5.3 Retail
- 1.5.4 Online
- 1.6 Market Analysis by Route of Administration
- 1.6.1 Overview: Global Spesolimab Consumption Value by Route of Administration: 2021 Versus 2025 Versus 2032
- 1.6.2 Intravenous Infusion, IV
- 1.6.3 Subcutaneous Injection, SC
- 1.7 Market Analysis by Application
- 1.7.1 Overview: Global Spesolimab Consumption Value by Application: 2021 Versus 2025 Versus 2032
- 1.7.2 Generalized Pustular Psoriasis (GPP)
- 1.7.3 Other Psoriasis-Related Inflammatory Conditions
- 1.7.4 IL-36-Mediated Inflammatory Skin Diseases
- 1.7.5 Others
- 1.8 Global Spesolimab Market Size & Forecast
- 1.8.1 Global Spesolimab Consumption Value (2021 & 2025 & 2032)
- 1.8.2 Global Spesolimab Sales Quantity (2021-2032)
- 1.8.3 Global Spesolimab Average Price (2021-2032)
2 Manufacturers Profiles
- 2.1 Boehringer Ingelheim
- 2.1.1 Boehringer Ingelheim Details
- 2.1.2 Boehringer Ingelheim Major Business
- 2.1.3 Boehringer Ingelheim Spesolimab Product and Services
- 2.1.4 Boehringer Ingelheim Spesolimab Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
- 2.1.5 Boehringer Ingelheim Recent Developments/Updates
- 2.2 Catalent
- 2.2.1 Catalent Details
- 2.2.2 Catalent Major Business
- 2.2.3 Catalent Spesolimab Product and Services
- 2.2.4 Catalent Spesolimab Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
- 2.2.5 Catalent Recent Developments/Updates
- 2.3 Lonza
- 2.3.1 Lonza Details
- 2.3.2 Lonza Major Business
- 2.3.3 Lonza Spesolimab Product and Services
- 2.3.4 Lonza Spesolimab Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
- 2.3.5 Lonza Recent Developments/Updates
3 Competitive Environment: Spesolimab by Manufacturer
- 3.1 Global Spesolimab Sales Quantity by Manufacturer (2021-2026)
- 3.2 Global Spesolimab Revenue by Manufacturer (2021-2026)
- 3.3 Global Spesolimab Average Price by Manufacturer (2021-2026)
- 3.4 Market Share Analysis (2025)
- 3.4.1 Producer Shipments of Spesolimab by Manufacturer Revenue ($MM) and Market Share (%): 2025
- 3.4.2 Top 3 Spesolimab Manufacturer Market Share in 2025
- 3.4.3 Top 6 Spesolimab Manufacturer Market Share in 2025
- 3.5 Spesolimab Market: Overall Company Footprint Analysis
- 3.5.1 Spesolimab Market: Region Footprint
- 3.5.2 Spesolimab Market: Company Product Type Footprint
- 3.5.3 Spesolimab Market: Company Product Application Footprint
- 3.6 New Market Entrants and Barriers to Market Entry
- 3.7 Mergers, Acquisition, Agreements, and Collaborations
4 Consumption Analysis by Region
- 4.1 Global Spesolimab Market Size by Region
- 4.1.1 Global Spesolimab Sales Quantity by Region (2021-2032)
- 4.1.2 Global Spesolimab Consumption Value by Region (2021-2032)
- 4.1.3 Global Spesolimab Average Price by Region (2021-2032)
- 4.2 North America Spesolimab Consumption Value (2021-2032)
- 4.3 Europe Spesolimab Consumption Value (2021-2032)
- 4.4 Asia-Pacific Spesolimab Consumption Value (2021-2032)
- 4.5 South America Spesolimab Consumption Value (2021-2032)
- 4.6 Middle East & Africa Spesolimab Consumption Value (2021-2032)
5 Market Segment by Type
- 5.1 Global Spesolimab Sales Quantity by Type (2021-2032)
- 5.2 Global Spesolimab Consumption Value by Type (2021-2032)
- 5.3 Global Spesolimab Average Price by Type (2021-2032)
6 Market Segment by Application
- 6.1 Global Spesolimab Sales Quantity by Application (2021-2032)
- 6.2 Global Spesolimab Consumption Value by Application (2021-2032)
- 6.3 Global Spesolimab Average Price by Application (2021-2032)
7 North America
- 7.1 North America Spesolimab Sales Quantity by Type (2021-2032)
- 7.2 North America Spesolimab Sales Quantity by Application (2021-2032)
- 7.3 North America Spesolimab Market Size by Country
- 7.3.1 North America Spesolimab Sales Quantity by Country (2021-2032)
- 7.3.2 North America Spesolimab Consumption Value by Country (2021-2032)
- 7.3.3 United States Market Size and Forecast (2021-2032)
- 7.3.4 Canada Market Size and Forecast (2021-2032)
- 7.3.5 Mexico Market Size and Forecast (2021-2032)
8 Europe
- 8.1 Europe Spesolimab Sales Quantity by Type (2021-2032)
- 8.2 Europe Spesolimab Sales Quantity by Application (2021-2032)
- 8.3 Europe Spesolimab Market Size by Country
- 8.3.1 Europe Spesolimab Sales Quantity by Country (2021-2032)
- 8.3.2 Europe Spesolimab Consumption Value by Country (2021-2032)
- 8.3.3 Germany Market Size and Forecast (2021-2032)
- 8.3.4 France Market Size and Forecast (2021-2032)
- 8.3.5 United Kingdom Market Size and Forecast (2021-2032)
- 8.3.6 Russia Market Size and Forecast (2021-2032)
- 8.3.7 Italy Market Size and Forecast (2021-2032)
9 Asia-Pacific
- 9.1 Asia-Pacific Spesolimab Sales Quantity by Type (2021-2032)
- 9.2 Asia-Pacific Spesolimab Sales Quantity by Application (2021-2032)
- 9.3 Asia-Pacific Spesolimab Market Size by Region
- 9.3.1 Asia-Pacific Spesolimab Sales Quantity by Region (2021-2032)
- 9.3.2 Asia-Pacific Spesolimab Consumption Value by Region (2021-2032)
- 9.3.3 China Market Size and Forecast (2021-2032)
- 9.3.4 Japan Market Size and Forecast (2021-2032)
- 9.3.5 South Korea Market Size and Forecast (2021-2032)
- 9.3.6 India Market Size and Forecast (2021-2032)
- 9.3.7 Southeast Asia Market Size and Forecast (2021-2032)
- 9.3.8 Australia Market Size and Forecast (2021-2032)
10 South America
- 10.1 South America Spesolimab Sales Quantity by Type (2021-2032)
- 10.2 South America Spesolimab Sales Quantity by Application (2021-2032)
- 10.3 South America Spesolimab Market Size by Country
- 10.3.1 South America Spesolimab Sales Quantity by Country (2021-2032)
- 10.3.2 South America Spesolimab Consumption Value by Country (2021-2032)
- 10.3.3 Brazil Market Size and Forecast (2021-2032)
- 10.3.4 Argentina Market Size and Forecast (2021-2032)
11 Middle East & Africa
- 11.1 Middle East & Africa Spesolimab Sales Quantity by Type (2021-2032)
- 11.2 Middle East & Africa Spesolimab Sales Quantity by Application (2021-2032)
- 11.3 Middle East & Africa Spesolimab Market Size by Country
- 11.3.1 Middle East & Africa Spesolimab Sales Quantity by Country (2021-2032)
- 11.3.2 Middle East & Africa Spesolimab Consumption Value by Country (2021-2032)
- 11.3.3 Turkey Market Size and Forecast (2021-2032)
- 11.3.4 Egypt Market Size and Forecast (2021-2032)
- 11.3.5 Saudi Arabia Market Size and Forecast (2021-2032)
- 11.3.6 South Africa Market Size and Forecast (2021-2032)
12 Market Dynamics
- 12.1 Spesolimab Market Drivers
- 12.2 Spesolimab Market Restraints
- 12.3 Spesolimab Trends Analysis
- 12.4 Porters Five Forces Analysis
- 12.4.1 Threat of New Entrants
- 12.4.2 Bargaining Power of Suppliers
- 12.4.3 Bargaining Power of Buyers
- 12.4.4 Threat of Substitutes
- 12.4.5 Competitive Rivalry
13 Raw Material and Industry Chain
- 13.1 Raw Material of Spesolimab and Key Manufacturers
- 13.2 Manufacturing Costs Percentage of Spesolimab
- 13.3 Spesolimab Production Process
- 13.4 Industry Value Chain Analysis
14 Shipments by Distribution Channel
- 14.1 Sales Channel
- 14.1.1 Direct to End-User
- 14.1.2 Distributors
- 14.2 Spesolimab Typical Distributors
- 14.3 Spesolimab Typical Customers
15 Research Findings and Conclusion
16 Appendix
- 16.1 Methodology
- 16.2 Research Process and Data Source
Summary:
Get latest Market Research Reports on Spesolimab. Industry analysis & Market Report on Spesolimab is a syndicated market report, published as Global Spesolimab Market 2026 by Manufacturers, Regions, Type and Application, Forecast to 2032. It is complete Research Study and Industry Analysis of Spesolimab market, to understand, Market Demand, Growth, trends analysis and Factor Influencing market.
REPORT YOU MIGHT BE INTERESTED
Related Reports
Reason to Buy
Reports and Markets
Contact Us
+1-352-353-0818 (US)Newsletter
KEEP UP TO DATE ON ALL THE LATEST REPORTS
